Left Atrial Appendage Occlusion
On this page
Direct answer
Why seal a small pocket at the mouth of the left atrium? Because in non-valvular atrial fibrillation the left atrial appendage generates the overwhelming majority of thrombi, and some patients simply cannot remain on anticoagulation for decades. Appendage occlusion with devices such as WATCHMAN offers them mechanical stroke prevention: PROTECT-AF showed non-inferiority to warfarin for the composite of stroke, systemic embolism and cardiovascular death, with superiority emerging by 45 months, while PREVAIL consolidated the finding. The trade-off is front-loaded procedural risk — pericardial effusion and tamponade were seen in roughly 5 per cent in early experience, falling with operator experience — and a structured post-implant antithrombotic programme: anticoagulation for about 45 days, then dual antiplatelet therapy to six months, then aspirin indefinitely, verified by transoesophageal echo before each step-down.
What you must remember
- Rationale: the appendage is the clot source in the large majority (over 90 per cent by classic autopsy and TEE series) of non-valvular AF strokes.
- Trials: PROTECT-AF non-inferior to warfarin; 45-month follow-up showed superiority; PREVAIL confirmed late safety; PRAGUE-17 suggested non-inferiority to direct oral anticoagulants.
- Indication: AF with elevated stroke risk (CHA2DS2-VASc-driven) and a genuine contraindication to long-term anticoagulation — prior major bleeding, high HAS-BLED with recurrent falls, or patient circumstances anticoagulation cannot survive.
- Contraindications: appendage thrombus on pre-procedure TEE, anatomy the device cannot seat, and any coexisting reason to anticoagulate lifelong (mechanical valve, moderate-to-severe rheumatic mitral stenosis).
- Post-implant protocol: oral anticoagulant for 45 days, TEE to confirm device position and leak under 5 mm, clopidogrel to six months, then lifelong aspirin.
- Peri-device leak: a residual flow jet of 5 mm or more, or peri-device flow exceeding the accepted threshold, postpones anticoagulant cessation.
- Complications: pericardial tamponade (air or wire perforation), device embolisation, stroke by air or thrombus — the first-day risks that anticoagulation cessation cannot be allowed to erase.
- Not for valvular AF: rheumatic MS and mechanical valves were excluded from every trial; these patients need warfarin regardless of any device.
A worked example: AF after intracranial haemorrhage
Picture a 72-year-old with hypertension and diabetes whose CHA2DS2-VASc score is 5, admitted with a moderate-sized parietal lobe haemorrhage while on apixaban. Six months later he has recovered, remains in AF with an appendage that fills and empties normally, and both neurologist and patient refuse lifelong anticoagulation. He is the textbook candidate.
The pathway runs: transoesophageal echo to exclude appendage thrombus and measure the landing zone; CT or TEE anatomy to size the device about 10-20 per cent oversize; percutaneous deployment via transseptal puncture with angiographic and echocardiographic confirmation of position and stability (the tug test); then the antithrombotic staircase. At 45 days, a TEE showing complete sealing or a leak under 5 mm allows anticoagulation to stop; clopidogrel continues to six months; aspirin forever. He stays on rate or rhythm control for his AF and on aggressive risk-factor management, because the device prevents appendage-origin stroke, not the atrial myopathy or the vascular disease behind it.
Where students slip
Two errors recur. The first is treating LAAO as a general alternative to anticoagulation — it is a compromise for those who cannot tolerate anticoagulation, and trials compared it against warfarin, not against nothing; patients who can take a DOAC safely should generally take the DOAC. The second is forgetting the valvular exclusions: a rheumatic mitral stenosis patient or a mechanical-valve patient with AF gets warfarin, full stop, and an appendage occluder is not a licence to stop it. Add the practical point examiners reward: the procedure replaces decades of bleeding risk with a concentrated early procedural risk, so consent must name tamponade, stroke and device embolisation explicitly, and the Indian cost of several lakh rupees out-of-pocket belongs in the same conversation.
Frequently asked questions
Who qualifies for left atrial appendage occlusion?
Patients with non-valvular AF at elevated stroke risk who have a contraindication to long-term anticoagulation, such as prior intracranial or major gastrointestinal bleeding.
What did PROTECT-AF demonstrate?
WATCHMAN was non-inferior to warfarin for stroke, systemic embolism and cardiovascular death, and superior on longer follow-up, at the cost of early pericardial effusion risk.
What antithrombotic regimen follows implantation?
Oral anticoagulation for about 45 days until TEE confirms sealing, then clopidogrel (plus aspirin) up to six months, then aspirin indefinitely.
When is a peri-device leak acceptable?
A leak under 5 mm is generally accepted with continuation of antiplatelet therapy; larger leaks usually mandate ongoing anticoagulation or reintervention.
Does appendage occlusion help in rheumatic mitral stenosis with AF?
No — rheumatic MS and mechanical valves were excluded from all landmark trials; these patients require lifelong vitamin K antagonist therapy.